一分钟看懂
这是一项关于多发性骨髓瘤的II 期研究，登记的药物或干预包括Cevostamab；Pomalidomide；Dexamethasone；Tocilizumab，当前状态为招募中。登记地点显示中国Jena有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Cevostamab；Pomalidomide；Dexamethasone；Tocilizumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Universitätsklinikum Jena, Klinik für Innere Medizin II · Jena
公开的入选条件
- * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to the start of administration of study treatment.
- * Received one to four lines of prior therapy, including prior B-cell maturation antigen (BCMA)-targeting Chimeric Antigen Receptors (CAR) T-cell therapy
- * Multiple Myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
- * Is triple-class exposed, i.e. received anti- cluster of differentiation 38 (CD38) therapy, a proteasome inhibitor (PI) and lenalidomide in any prior line
- * Participants must have measurable disease during screening
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07825064；登记信息更新于 2026-09-17。